Literature DB >> 27808480

Prevalence and characteristics of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus nasal colonization among a community-based diabetes population in Foshan, China.

Jialing Lin1, Ping Xu1, Yang Peng2, Dongxin Lin1, Qianting Ou1, Ting Zhang1, Chan Bai1, Xiaohua Ye1, Junli Zhou1, Zhenjiang Yao1.   

Abstract

AIMS/
INTRODUCTION: Evidence suggests that diabetes might cause an increase in colonization of Staphylococcus aureus (S. aureus) and methicillin-resistant S. aureus (MRSA) in community settings. We carried out a cross-sectional study to determine the prevalence and influencing factors of S. aureus and MRSA nasal colonization among a community-based diabetes population, and to identify the characteristics of the isolated strains.
MATERIALS AND METHODS: A total of 956 participants from 11 community settings were included in the study.
RESULTS: Of the 529 diabetes participants, 46 were colonized with S. aureus and 22 were colonized with MRSA. Of the 427 non-diabetes participants, 25 were colonized with S. aureus and 12 were colonized with MRSA. Men (odds ratio 0.45, 95% confidence interval 0.20-0.99, P = 0.047) were less likely to have S. aureus nasal colonization, and those with well-controlled blood glucose (odds ratio 2.04, 95% confidence interval 1.01-4.13, P = 0.047) among the diabetes population were more likely to have S. aureus nasal colonization. The proportion of multidrug-resistant S. aureus strains in the diabetes population (52.17%) was higher than that in the non-diabetes population (28.00%; χ2 = 3.848, P = 0.050). The most common clonal complex type and Staphylococcal chromosome cassette mec type of MRSA in diabetes population was clonal complex 5 (40.91%) and type IV (27.27%), respectively. The proportion of Panton-Valentine leukocidin gene in MRSA strains was 17.65%. There was great sequence type diversity in MRSA strains.
CONCLUSIONS: The prevalence of MRSA in the community-based diabetes population was moderate, and the high proportions of multidrug-resistant S. aureus strains and diverse molecular characteristics in the diabetes population should be noticed.
© 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  zzm321990Staphylococcus aureuszzm321990; Diabetes; Methicillin-resistant Staphylococcus aureus

Mesh:

Year:  2016        PMID: 27808480      PMCID: PMC5415482          DOI: 10.1111/jdi.12591

Source DB:  PubMed          Journal:  J Diabetes Investig        ISSN: 2040-1116            Impact factor:   4.232


Introduction

Staphylococcus aureus, one of the most frequently occurring community‐ and hospital‐associated pathogens, can cause infectious diseases including mild skin infection, endocarditis and even fulminant septicemia1, 2, 3. S. aureus is a normal inhabitant of the nose, throat and oral cavity4, 5. With the widespread use of antibiotics, methicillin‐resistant S. aureus (MRSA) infections have become significant causes of morbidity and mortality both in the hospital and community settings6, 7, 8. Remarkably, investigations have reported that community‐associated MRSA infections are increasing9, 10, 11. The prevalence of diabetes, especially type 2 diabetes mellitus, is increasing at a worrying rate in the world. In 2013, 382 million people had diabetes worldwide, and this number is expected to increase to 592 million by 203512. Approximately 80% of diabetes patients are in low‐ and middle‐income countries12. As a developing country, China has a large burden of diabetes: one in four people had the disease in 201313. Furthermore, evidence suggests that diabetes can cause an increased colonization of S. aureus and MRSA in both hospitals14, 15, 16, 17 and community settings18, 19. However, investigations regarding S. aureus and MRSA nasal colonization among diabetes population are limited, and most of them are focused on the patients in hospitals17, 20, 21. Therefore, the aim of the present cross‐sectional study was to determine the prevalence, influencing factors and molecular epidemiology of S. aureus and MRSA nasal colonization among a community‐based diabetes population in Foshan, Guangdong province, China.

Materials and methods

Ethics Statement

This study was approved by the ethics committee of Guangdong Pharmaceutical University, and it was carried out in accordance with the approved guidelines. All participants signed an informed consent form.

Study Design and Population

A cross‐sectional study was carried out between April 2014 and May 2015 in 11 community settings (Ganjiao community, Xinxing community, Dachong community, Hecun community, Mashe community, Shachong community, Honggang community, Ganglian community, Shengli community, Zhoucun community and Jinxi community) in Guangdong province, China. Those with clinically diagnosed diabetes were voluntarily included in the study. According to the diagnosis of diabetes by the World Health Organization and International Diabetes Federation, diabetes was diagnosed by fasting plasma glucose ≥7.00 mmol/L and/or 2 h postprandial plasma glucose ≥11.10 mmol/L. Additionally, diabetes participants were regarded as having well‐controlled blood glucose when they had glycosylated hemoglobin <6.5%. Furthermore, we randomly selected the non‐diabetes population from the same area, with the same sex and age ranges within 5 years as controls. We excluded participants who had used antibiotics within a week, had acute diseases, had significant wounds or had other private reasons for exclusion.

Data Collection and Processing

After obtaining informed consent, a face‐to‐face questionnaire was administered to collect relevant information. Five trained interviewers used a structured questionnaire to collect demographic, behavioral and medical history information from participants. In addition, interviewers extracted relevant data from their patient medical records. During the interview, we inserted a sterile swab moistened with normal saline into each participant's anterior nostrils to a depth of approximately 1.5 cm, and rotated the swab five times. For each specimen, we sampled both nostrils consecutively using the same swab. Each swab was placed into a sterile tube with 7.5% sodium chloride broth, and the tubes were transported to the laboratory immediately after sampling. After 24 h of incubation at 37°C, the swabs were transferred to mannitol salt agar plates for another 24 h of incubation. We then took all samples to be screened for S. aureus by colony morphology, Gram staining, catalase test, deoxyribonuclease test and coagulase tests. All S. aureus strains were tested to identify MRSA. Those S. aureus strains that were positive for the mecA gene22 and/or resistance to cefoxitin23 were identified as MRSA. And those S. aureus strains that were negative for the mecA gene22 and sensitive to cefoxitin23 were identified as methicillin‐sensitive S. aureus.

Antibiotic Susceptibility Test

All S. aureus isolates were assessed for susceptibility to a panel of 11 antibiotics, including cefoxitin, clindamycin, penicillin, linezolid, gentamycin, teicoplanin, erythromycin, rifampicin, tobramycin, moxifloxacin, nitrofurantoin, linezolid and trimethoprim‐sulfamethoxazol. The Kirby–Bauer disk diffusion method was used to test susceptibility to all antibiotics, and diameter interpretations were based on the protocol of the Clinical and Laboratory Standards Institute guidelines (2015)23. Strains were classified as multidrug resistant (MDR) if they were non‐susceptible to ≥3 antibiotics with different mechanisms of action (note that these strains are already resistant to all beta‐lactam antibiotics)24.

Molecular Characterization

We carried out polymerase chain reaction tests targeting the Panton–Valentine Leukocidin (PVL) toxin gene and the Staphylococcal cassette chromosome mec (SCCmec) type, using the previously described primers22, 25. Multilocus sequence typing of the seven housekeeping genes was carried out using the previously described primers and protocols26. The sequence type was determined for each isolate by comparing the sequence obtained to known alleles at each locus in the multilocus sequence typing database (http://saureus.mlst.net), and clonal complexes (CCs) were determined using the eBURST algorithm (http://eburst.mlst.net)27.

Statistical Analysis

Means and standard errors were calculated for continuous variables, and frequencies (percentages) were calculated for categorical variables. Continuous variables were compared by the Student's t‐test. Categorical variables were compared by Pearson's χ2‐test or Fisher's exact test when appropriate. The relationships between influencing factors and S. aureus and MRSA nasal colonization were examined using multivariable logistic regression models. We carried out the multivariable logistic regression analysis of all variables with a P‐value of <0.05, and then removed variables that were not significant at this level. All analyses were carried out using stata version 13.1 (StataCorp LP, College Station, TX, USA), and a two‐sided P‐value for statistical significance was defined as P < 0.05.

Results

Study Population

A total of 956 participants were included in the study. Of those, 529 were the diabetes population and 427 were the non‐diabetes population. There were 161 (30.43%) men and 368 (69.57%) women in the diabetes population, whereas there were 181 (42.39%) men and 246 (57.61%) women in the non‐diabetes population. With regard to the average age, the diabetes population was aged 66.13 ± 9.34 years (men 66.12 ± 9.84 years, women 66.14 ± 9.13 years), and the non‐diabetes population was aged 64.39 ± 9.45 years (men 65.58 ± 9.85 years, women 63.51 ± 9.07 years). There was a statistically significant difference between the two populations with regard to age (t = 2.85, P = 0.002), and this discrepancy was adjusted by applying the multivariable logistic regression model. Of the 529 diabetes participants, 46 (8.70%) were colonized with S. aureus and 22 (4.16%) were colonized with MRSA. Of the 427 non‐diabetes participants, 25 (5.85%) were colonized with S. aureus and 12 (2.81%) were colonized with MRSA. There was no statistically significant difference between the two populations with regard to S. aureus and MRSA nasal colonization. After adjusted for sex and age, the prevalence of S. aureus and MRSA nasal colonization among the diabetes and non‐diabetes population were 8.09%, 3.70%, and 5.70%, 2.69%, respectively. There was no statistically significant difference between the adjusted and unadjusted prevalence. More details can be found in Table 1.
Table 1

Prevalence of Staphylococcus aureus and methicillin‐resistant Staphylococcus aureus nasal colonization

Population n S. aureus MRSA
n (%)Adjusteda χ2 P‐value n (%)Adjusteda χ2 P‐value
Diabetes52946 (8.70%)8.09%2.770.09622 (4.16%)3.70%1.250.263
Non‐diabetes42725 (5.85%)5.70%12 (2.81%)2.69%

Prevalence after adjusted for sex and age. MRSA, methicillin‐resistant Staphylococcus aureus; S. aureus, Staphylococcus aureus.

Prevalence of Staphylococcus aureus and methicillin‐resistant Staphylococcus aureus nasal colonization Prevalence after adjusted for sex and age. MRSA, methicillin‐resistant Staphylococcus aureus; S. aureus, Staphylococcus aureus.

Influencing Factors of S. aureus and MRSA Nasal Colonization in the Diabetes Population

We found that women (χ2 = 4.05, P = 0.044) and well‐controlled blood glucose (χ2 = 4.03, P = 0.045) were associated with S. aureus nasal colonization among the diabetic population. Women (10.33%) were more likely than men (4.97%) to have S. aureus nasal colonization. Those with well‐controlled blood glucose (10.61%) were more likely to have S. aureus nasal colonization than those without well‐controlled blood glucose (5.53%). However, no influencing factor was associated with MRSA nasal colonization among the diabetic population in the present study. More details can be found in Table 2.
Table 2

Influencing factors of Staphylococcus aureus and methicillin‐resistant Staphylococcus aureus nasal colonization among the diabetic population

Influencing factors n S. aureus MRSA
n (%)χ2 P‐value n (%)χ2 P‐value
Demographic characteristics
Sex
Men1618 (4.97)4.050.0443 (1.86)3.060.080
Women36838 (10.33)19 (5.16)
Age (years)
≤6526725 (9.36)0.300.58212 (4.49)0.150.696
>6526221 (8.02)10 (3.82)
BMI
<18.5291 (3.45)1.720.6321 (3.45)3.380.337
18.5–24.921517 (7.91)11 (5.12)
25–27.921020 (9.52)5 (2.38)
≥28758 (10.67)5 (6.67)
Monthly income (yuan)
<200046940 (8.53)0.20918 (3.84)0.197
2000–2999436 (13.95)4 (9.30)
≥3000170 (0.00)0 (0.00)
Education
Illiterate9111 (12.09)1.600.4497 (7.69)
Primary school32826 (7.93)11 (3.35)0.197
Junior school and above1109 (8.18)4 (3.64)
Medical history
Type of diabetes
1190 (0.00)0.3960 (0.00)1.000
250746 (9.07)22 (4.34)
Duration of diabetes (years)
<533232 (9.64)3.400.18317 (5.12)0.120
5–91135 (4.42)1 (0.88)
≥10849 (10.71)4 (4.76)
Family history of diabetes
Yes10912 (11.01)0.930.3373 (2.75)0.591
No42034 (8.1)19 (4.52)
Blood glucose monitoring
Yes27126 (9.59)0.5650.45312 (4.43)0.100.751
No25820 (7.75)10 (3.88)
Blood glucose controlling
Yes51345 (8.77)1.00022 (4.29)1.000
No161 (6.25)0 (0.00)
Well‐controlled blood glucose
Yes33035 (10.61)4.030.04518 (5.45)3.700.055
No19911 (5.53)4 (2.01)
Taking insulin now
Yes18616 (8.60)0.010.95510 (5.38)1.070.302
No34330 (8.75)12 (3.50)
Behavioral characteristics
Smoking
Yes773 (3.90)2.610.1062 (2.60)0.756
No45243 (9.51)20 (4.42)
Taking alcohol drinks
Yes260 (0.00)0.1540 (0.00)0.617
No50346 (9.15)22 (4.37)
Taking physical activity
Yes38634 (8.81)0.020.88019 (4.92)2.090.149
No14312 (8.39)3 (2.10)
Antibiotic use past year
Yes1218 (6.61)0.860.3555 (4.13)0.000.987
No40838 (9.31)17 (4.17)
Hospitalization past year
Yes24423 (9.43)0.410.52311 (4.51)0.110.742
No28022 (7.86)11 (3.93)

–, Calculated with Fisher's exact test; BMI, body mass index (weight [kg] / height [m]2); MRSA, methicillin‐resistant Staphylococcus aureus; S. aureus, Staphylococcus aureus.

Influencing factors of Staphylococcus aureus and methicillin‐resistant Staphylococcus aureus nasal colonization among the diabetic population –, Calculated with Fisher's exact test; BMI, body mass index (weight [kg] / height [m]2); MRSA, methicillin‐resistant Staphylococcus aureus; S. aureus, Staphylococcus aureus. To account for potential confounding among the influencing factors, we further analyzed the relationship between the potential predictors with a logistic regression model. This model showed that when controlling for the effects of the other influencing factors, the relationships found in the univariable analyses did not change. The male diabetes population was less likely to have S. aureus nasal colonization (odds ratio 0.45, 95% confidence interval 0.20–0.99, P = 0.047). Those with well‐controlled blood glucose were more likely to have S. aureus nasal colonization (odds ratio 2.04, 95% confidence interval 1.01–4.13, P = 0.047). More details can be found in Table 3.
Table 3

Logistic regression analysis of influencing factors in Staphylococcus aureus nasal colonization among diabetic population

Influencing factorsOR P‐value95% CI
Sex
Men0.450.0470.20–0.99
Women1.00
Well‐controlled blood glucose
Yes2.040.0471.01–4.13
No1.00

CI, confidence interval; OR, odds ratio.

Logistic regression analysis of influencing factors in Staphylococcus aureus nasal colonization among diabetic population CI, confidence interval; OR, odds ratio.

Antibiotic Resistance of S. aureus Nasal Colonization

The highest proportion of antibiotic resistance in S. aureus nasal colonization among the diabetes population was to penicillin (89.13%), followed by erythromycin (73.91%), teicoplanin (65.22%), clindamycin (43.48%), tobramycin (26.09%), moxifloxacin (23.91%), cefoxitin (21.74%), gentamycin (19.57%), trimethoprim‐sulfamethoxazol (13.04%), rifampicin (10.87%) and linezolid (2.17%). With regard to the non‐diabetes population, the highest proportion of antibiotic resistance in S. aureus nasal colonization was to penicillin (96.00%), followed by clindamycin (60.00%), erythromycin (46.00%), teicoplanin (36.00%), tobramycin (32.00%), cefoxitin (24.00%), rifampicin (24.00%), moxifloxacin (16.00%), gentamycin (12.00%), trimethoprim‐sulfamethoxazol (12.00%) and linezolid (0.00%). Furthermore, the proportion of MDR S. aureus strains in the diabetes population (52.17%, 24/46) was higher than that in the non‐diabetes population (28.00%, 7/25) (χ2 = 3.848, P = 0.050). The highest proportion of antibiotic resistance in MRSA nasal colonization among the diabetes population was to penicillin (95.45%), followed by erythromycin (81.82%), teicoplanin (59.09%), clindamycin (59.09%), cefoxitin (45.45%), moxifloxacin (36.36%), tobramycin (31.82%), gentamycin (27.27%), trimethoprim‐sulfamethoxazol (22.73%), rifampicin (13.64%) and linezolid (4.55%). With regard to the non‐diabetes population, the highest proportion of antibiotic resistance in MRSA nasal colonization was to penicillin (100.00%), followed by erythromycin (75.00%), clindamycin (66.67%), cefoxitin (50.00%), teicoplanin (33.33%), moxifloxacin (33.33%), tobramycin (25.00%), trimethoprim‐sulfamethoxazol (25.00%), rifampicin (16.67%), gentamycin (16.67%) and linezolid (0.00%). There were statistically significant differences between the two populations in antibiotic resistance of S. aureus nasal colonization with regard to teicoplanin (χ2 = 5.59, P = 0.018) and erythromycin (χ2 = 4.77, P = 0.029). S. aureus strains were more likely to be resistant to teicoplanin and erythromycin in the diabetes population than those in the non‐diabetes population. More details can be found in Table 4.
Table 4

Antibiotic resistance of Staphylococcus aureus nasal colonization

AntibioticDiabetic populationNon‐diabetic population P‐value* P‐value**
MRSA (n = 22)MSSA (n = 24)MRSA (n = 12)MSSA (n = 13)
Cefoxitin10 (45.45)0 (0.00)6 (50.00)0 (0.00)0.8280.800
Linezolid1 (4.55)0 (0.00)0 (0.00)0 (0.00)1.000*** 1.000***
Penicillin21 (95.45)20 (83.33)12 (100.00)12 (92.31)0.3200.453
Gentamycin6 (27.27)3 (12.50)2 (16.67)1 (7.69)0.4170.486
Teicoplanin13 (59.09)17 (70.83)4 (33.33)5 (38.46)0.0180.151
Erythromycin18 (81.82)16 (66.67)9 (75.00)3 (23.08)0.0290.638
Trimethoprim‐sulfamethoxazol5 (22.73)1 (4.17)3 (25.00)0 (0.00)0.9000.881
Tobramycin7 (31.82)5 (20.83)3 (25.00)5 (38.46)0.5970.677
Moxifloxacin8 (36.36)3 (12.50)4 (33.33)0 (0.00)0.4350.860
Rifampicin3 (13.64)2 (8.33)2 (16.67)4 (30.77)0.1440.812
Clindamycin13 (59.09)7 (29.17)8 (66.67)7 (53.85)0.1840.664

Data presented as n (%). *P‐value was calculated the antibiotic resistance proportions of Staphylococcus aureus between the two populations.

**P‐value was calculated the antibiotic resistance proportions of methicillin‐resistant Staphylococcus aureus (MRSA) between the two populations.

***P‐value was calculated with Fisher's exact test. MSSA, methicillin‐sensitive Staphylococcus aureus.

Antibiotic resistance of Staphylococcus aureus nasal colonization Data presented as n (%). *P‐value was calculated the antibiotic resistance proportions of Staphylococcus aureus between the two populations. **P‐value was calculated the antibiotic resistance proportions of methicillin‐resistant Staphylococcus aureus (MRSA) between the two populations. ***P‐value was calculated with Fisher's exact test. MSSA, methicillin‐sensitive Staphylococcus aureus.

Genotypic and Phenotypic Characteristics of MRSA Nasal Colonization

The most common CC type of MRSA in the 22 members of the diabetes population was CC5 (9), followed by CC398 (5), CC59 (4), CC45 (2), CC30 (1) and CC182 (1). The most common CC type of MRSA in the 12 members of the non‐diabetes population was CC5 (5), followed by CC59 (3), CC7 (1), CC30 (1) and CC88 (1). We identified 19 unique STs from 34 MRSA strains. MRSA strains from the diabetes population showed great ST diversity. ST59 was common among the two populations. ST398 was common among the diabetes population, but absent from the non‐diabetes population. Among the 34 MRSA strains, the predominant ST was ST398 for the diabetes population and ST544 for the non‐diabetes population. The most common SCCmec type of MRSA strains in the diabetes population was type IV (27.27%), followed by non‐typeable (22.73%), type V (18.18%), type II (13.64%), type III (13.64%) and type I (4.54%). The most common SCCmec type of MRSA strains in the non‐diabetes population was type IV (58.34%), followed by type III (16.67%), non‐typeable (8.33%), type V (8.33%), type II (8.33%) and type I (0.00%). The proportion of the virulence gene PVL of the MRSA strains in the diabetes population (13.64%, 3/22) was lower than that in the non‐diabetes population (25.00%, 3/12). The patterns of MDR in the diabetes population and non‐diabetes population were different. More details can be found in Table 5.
Table 5

Genotypic and phenotypic characteristics of methicillin‐resistant Staphylococcus aureus nasal colonization

PopulationCCMLSTSCCmec PVLMDRAntibiotic resistance patterns
Diabetes (n = 22)CC5ST544IV+PEN‐GEN‐TEC‐TOB
CC5ST1NT+PEN‐TEC‐ERY‐SXT‐TOB‐MXF‐CLI
CC5ST1II+FOX‐PEN‐GEN‐ERY‐TOB‐MXF‐CLI
CC5ST6NT+
CC5ST6IPEN‐TEC‐CLI
CC5ST5V+PEN‐GEN‐ERY‐SXT‐CLI
CC5ST72IVFOX‐PEN‐ERY
CC5ST9IV+FOX‐PEN‐GEN‐ERY‐SXT‐TOB‐CLI
CC5ST188NTPEN‐TEC
CC30ST30IVPEN‐TEC‐ERY
CC45ST45IV+FOX‐PEN‐TEC‐ERY‐CLI
CC45ST3154NTFOX‐PEN‐TEC‐ERY
CC59ST338III++FOX‐PEN‐TEC‐ERY‐MXF‐CLI
CC59ST338III++FOX‐PEN‐ERY‐SXT‐CLI
CC59ST59IV+LZD‐FOX‐PEN‐ERY‐MXF‐CLI
CC59ST59V+FOX‐PEN‐TEC‐ERY‐MXF‐CLI
CC182ST944IIPEN‐ERY‐CLI
CC398ST398V+PEN‐GEN‐ERY‐SXT‐TOB‐MXF‐CLI
CC398ST2504V+PEN‐GEN‐TEC‐ERY‐TOB‐MXF‐CLI
CC398ST1937II+FOX‐PEN‐TEC‐ERY‐MXF‐CLI
CC398ST398III+PEN‐TEC‐ERY‐CLI
CC398ST398NT+PEN‐TEC‐ERY‐TOB
Non‐diabetes (n = 12)CC5ST9IV+FOX‐PEN‐GEN‐TEC‐ERY‐SXT‐TOB‐MXF‐RIF‐CLI
CC5ST544IVPEN
CC5ST544IV+PEN‐TEC
CC5ST72II+PEN‐TEC‐ERY‐MXF‐CLI
CC5ST5V+FOX‐PEN‐ERY‐MXF‐CLI
CC7ST7IV+PEN‐GEN‐ERY‐SXT‐TOB‐CLI
CC30ST30IVPEN‐ERY‐MXF
CC59ST59IVFOX‐PEN‐ERY‐CLI
CC59ST59IVFOX‐PEN‐ERY‐CLI
CC59ST338III+FOX‐PEN‐ERY‐CLI
CC88ST88NT++FOX‐PEN‐ERY‐SXT‐TOB‐RIF‐CLI
CC2483ST2483IIIPEN‐TEC

+, Positive; –, negative; CC, clonal complex; CLI, clindamycin; ERY, erythromycin; FOX, cefoxitin; GEN, gentamycin; LZD, linezolid; MDR, multidrug resistant; MLST, multilocus sequence typing; MXF, moxifloxacin; NT, non‐typeable; PEN, penicillin; PVL, Panton–Valentine leukocidin; RIF, rifampicin; SCC, staphylococcal chromosome cassette; ST, sequence type; SXT, trimethoprim‐sulfamethoxazol; TEC, teicoplanin; TOB, tobramycin.

Genotypic and phenotypic characteristics of methicillin‐resistant Staphylococcus aureus nasal colonization +, Positive; –, negative; CC, clonal complex; CLI, clindamycin; ERY, erythromycin; FOX, cefoxitin; GEN, gentamycin; LZD, linezolid; MDR, multidrug resistant; MLST, multilocus sequence typing; MXF, moxifloxacin; NT, non‐typeable; PEN, penicillin; PVL, Panton–Valentine leukocidin; RIF, rifampicin; SCC, staphylococcal chromosome cassette; ST, sequence type; SXT, trimethoprim‐sulfamethoxazol; TEC, teicoplanin; TOB, tobramycin.

Discussion

The present study adds to the existing knowledge by giving insight into the genotypic and phenotypic characteristics of S. aureus and MRSA nasal colonization among the diabetes population in community settings. The prevalence of S. aureus (8.70%, 46/529) nasal colonization among the community‐based diabetes population in this study was lower than those of a diabetic outpatient population in Turkey (41.78%, 127/304)21, long‐term hemodialysis type 2 diabetes patients in Saudi Arabia (72.41%, 42/58)28, hospitalized diabetic patients in India (56.67%, 34/60)17, diabetes patients in Australia (39.09%, 258/660)19, hospitalized diabetic patients (20.50%, 41/200) in China20 and type 2 diabetes outpatients in China (10.31%, 43/417)21. The prevalence of MRSA (4.16%, 22/529) nasal colonization among the community‐based diabetes population in this study was lower than those of type 2 diabetes patients in China (5.28%, 22/417)18, a diabetic outpatient population in Turkey (9.87%, 30/304)21 and long‐term hemodialysis type 2 diabetes patients in Saudi Arabia (18.97%, 11/58)28, but was higher than those of hospitalized diabetic patients in China (0.50%, 1/200)20, diabetes patients in Australia (1.21%, 8/660)19 and type 1 diabetes pediatric outpatients in Turkey (in 2005, 0.99%, 1/101; in 2013, 0.75%, 1/134)29. From the aforementioned statistics, we know that the prevalence of S. aureus nasal colonization was lower in this community‐based diabetes population than in the hospital‐based diabetes population. The proportion of MRSA nasal colonization in S. aureus strains (47.83%, 22/46) among the diabetes population in the present study was higher than the nationally average proportion of MRSA in S. aureus strains in 2013 (45.20%)30 and 2014 (44.60%)31 in China, which can be partially explained by the high prevalence of MRSA nasal colonization in the present community‐based diabetes population. However, there was no statistical difference in the prevalence of S. aureus and MRSA nasal colonization between the two populations, which was consistent with several studies19, 32. The multivariable logistic regression model showed that women and well‐controlled blood glucose were associated with a higher prevalence of S. aureus nasal colonization among the diabetes population, which was different to some other studies. Most of the existing studies reported that sex was irrelevant to the prevalence of S. aureus nasal colonization among diabetes populations19, 21, 32, 33, 34, which was contrary to the present study. The possible reasons were that the majority of included diabetes patients in the present study were women, and the women were older than the men. Furthermore, there were studies35, 36 that showed that women with older age had weaker immune systems and were more likely to be infected with many infectious diseases, which might be the reason for this result. With regard to the relationship between well‐controlled blood glucose and the prevalence of S. aureus nasal colonization among the diabetes population, it varied in different countries and regions. It was reported as a protective factor21, a risk factor33, 37 or an irrelevant factor19, 32. This might have resulted from the different races, sample size, therapies and other elements, so it requires further investigation. We found that S. aureus strains of both the diabetes population and non‐diabetes population in the present study were highly resistant to erythromycin and penicillin, which was similar to several other studies20, 38, 39. This might be as a result of the extensive use of these antibiotics in medical institutions. We also found that 54.93% of S. aureus strains were resistant to teicoplanin, which was higher than several studies40. The reason for the high rate of teicoplanin resistance might partly be due to the standard of antibiotic resistance, which included both intermediate and resistant strains in the present study, which caused the high rate of teicoplanin resistance. Furthermore, the proportion of MDR S. aureus strains in the diabetes population (52.17%) was higher than that in the non‐diabetes population (28.00%), which should be noticed by healthcare workers to reasonably utilize antibiotics. There were studies that reported that the PVL toxin gene was related to skin soft tissue infection and necrotizing pneumonia41, 42, 43. Of 34 MRSA strains, six (17.65%) were positive to it. However, there was no statistical difference between the two populations. The most common SCCmec type in the two populations was type IV, which was consistent with the source of the two populations. ST59 was common among MRSA strains from the two populations, which was consistent with a study that ST59 was mainly in community settings from the Asian area44. ST398, which was mainly from swine in North America and Europe45, 46, but found in humans in China47, 48, was common among the diabetes population, which might be associated with poor immune function in the diabetes population. The CC types among the two community‐based populations were diverse. CC5, the most common CC type of MRSA strains in the two community‐based populations, was reported to be the main CC type among MRSA infection in hospital settings49, 50, which might indicate that there were hospital‐associated MRSA in these 11 community settings. There were several limitations to the present study. First, we did not follow up the outcomes of S. aureus and MRSA nasal colonization among the diabetes population because of limited financial support. Second, we did not investigate the environmental factors, which might be potential influencing factors of S. aureus and MRSA nasal colonization, because of limited human resources. Finally, we did not use an MIC method because of limited financial support, and we will further consider it in future research. There was no statistical difference of S. aureus and MRSA nasal colonization between the community‐based diabetes population and non‐diabetes population. Women and those with well‐controlled blood glucose in the community‐based diabetes population were more likely to have S. aureus and MRSA nasal colonization. The majority of antibiotic resistance proportions in MRSA strains were higher than those in the methicillin‐sensitive S. aureus strains. The proportions of MDR S. aureus and MRSA strains were higher in the diabetes population than in the non‐diabetes population. The proportion of the PVL toxin gene in MRSA strains was moderate. MRSA strains in the present study were mainly from community settings, but there were some strains from hospital settings. There was great ST diversity in MRSA strains among the community‐based diabetes population, and this was closely related to internationally epidemiological strains. Therefore, the present results suggest a need for surveillance of MDR S. aureus and MRSA in community‐based diabetes populations. More research is still required to establish the exact transmission routes and explore measures for preventing the spread of the bacterium in community settings.

Disclosure

The authors declare no conflict of interest.
  45 in total

1.  Staphylococcus aureus and the oral cavity: an overlooked source of carriage and infection?

Authors:  M G McCormack; A J Smith; A N Akram; M Jackson; D Robertson; G Edwards
Journal:  Am J Infect Control       Date:  2015-01       Impact factor: 2.918

2.  Risk factors for and impact of methicillin-resistant Staphylococcus aureus nasal colonization in patients in a medical intensive care unit.

Authors:  Christina C Chen; Steven E Pass
Journal:  Am J Infect Control       Date:  2013-05-08       Impact factor: 2.918

3.  CA-MRSA Infection Incidence and Care in High School and Intercollegiate Athletics.

Authors:  Tim Braun; Leamor Kahanov; Kathleen Dannelly; Christine Lauber
Journal:  Med Sci Sports Exerc       Date:  2016-08       Impact factor: 5.411

4.  Prevalence and risk factors for methicillin-resistant Staphylococcus aureus colonization in a diabetic outpatient population: a prospective cohort study.

Authors:  Selda Sayin Kutlu; Nural Cevahir; Serife Akalin; Fulya Akin; Selmin Dirgen Caylak; Mehmet Bastemir; Koray Tekin
Journal:  Am J Infect Control       Date:  2011-08-23       Impact factor: 2.918

5.  Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus skin and soft tissue infection in a Canadian emergency department.

Authors:  Robert Stenstrom; Eric Grafstein; Marc Romney; Jahan Fahimi; Devin Harris; Garth Hunte; Grant Innes; Jim Christenson
Journal:  CJEM       Date:  2009-09       Impact factor: 2.410

6.  Staphylococcus aureus nasal carriage and associated factors in type 2 diabetic patients.

Authors:  Ali Tamer; Oguz Karabay; Hasan Ekerbicer
Journal:  Jpn J Infect Dis       Date:  2006-02       Impact factor: 1.362

7.  Incidence and risk factors for community-associated methicillin-resistant Staphylococcus aureus in New York City, 2006-2012.

Authors:  P Baker; B Cohen; J Liu; E Larson
Journal:  Epidemiol Infect       Date:  2015-09-14       Impact factor: 2.451

8.  Diabetes in China: a societal solution for a personal challenge.

Authors:  Juliana C N Chan; Yuying Zhang; Guang Ning
Journal:  Lancet Diabetes Endocrinol       Date:  2014-09-10       Impact factor: 32.069

Review 9.  New epidemiology of Staphylococcus aureus infection in Asia.

Authors:  C-J Chen; Y-C Huang
Journal:  Clin Microbiol Infect       Date:  2014-07       Impact factor: 8.067

10.  Methicillin-Resistant Staphylococcus aureus Associated with Animals and Its Relevance to Human Health.

Authors:  Annalisa Pantosti
Journal:  Front Microbiol       Date:  2012-04-09       Impact factor: 5.640

View more
  6 in total

1.  The Evolution of Breast Implant Infections: Serratia marcescens Is an Emerging Pathogen in Implant-Based Breast Reconstruction.

Authors:  Jane L Gui; Kant Y Lin
Journal:  Plast Surg (Oakv)       Date:  2019-02-21       Impact factor: 0.947

2.  Prevalence and characteristics of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus nasal colonization among a community-based diabetes population in Foshan, China.

Authors:  Jialing Lin; Ping Xu; Yang Peng; Dongxin Lin; Qianting Ou; Ting Zhang; Chan Bai; Xiaohua Ye; Junli Zhou; Zhenjiang Yao
Journal:  J Diabetes Investig       Date:  2016-12-15       Impact factor: 4.232

3.  The prevalence of methicillin-resistant Staphylococcus aureus among diabetic patients: a meta-analysis.

Authors:  Helen J Stacey; Caitlin S Clements; Susan C Welburn; Joshua D Jones
Journal:  Acta Diabetol       Date:  2019-04-06       Impact factor: 4.280

4.  Antimicrobial resistance, virulence genes profiling and molecular relatedness of methicillin-resistant Staphylococcus aureus strains isolated from hospitalized patients in Guangdong Province, China.

Authors:  Yingjian Liang; Changli Tu; Cuiyan Tan; Mohamed Abd El-Gawad El-Sayed Ahmed; Min Dai; Yong Xia; Yan Liu; Lan-Lan Zhong; Cong Shen; Guanping Chen; Guo-Bao Tian; Jing Liu; Xiaobin Zheng
Journal:  Infect Drug Resist       Date:  2019-02-25       Impact factor: 4.003

Review 5.  Virulence factors and clonal diversity of Staphylococcus aureus in colonization and wound infection with emphasis on diabetic foot infection.

Authors:  Kavitha Shettigar; Thokur Sreepathy Murali
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-07-18       Impact factor: 3.267

6.  The microbiology of diabetic foot infections: a meta-analysis.

Authors:  Katherine E Macdonald; Sophie Boeckh; Helen J Stacey; Joshua D Jones
Journal:  BMC Infect Dis       Date:  2021-08-09       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.